Standout Papers

Effect of Linagliptin vs ... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
    2019 392 citations Julio Rosenstock, Steven E. Kahn et al. JAMA profile →

Immediate Impact

68 hit
Sub-graph 1 of 21

Citing Papers

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
2025 Hit
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
2025 Hit
1 intermediate paper

Works of Annett Keller being referenced

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
2019 Hit

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Annett Keller 400 124 107 80 68 7 458
Christina Stahre 413 1.0× 174 1.4× 152 1.4× 88 1.1× 91 1.3× 12 523
Rishi Patel 447 1.1× 182 1.5× 165 1.5× 61 0.8× 18 0.3× 9 534
Sudipta Bhattacharya 391 1.0× 168 1.4× 132 1.2× 20 0.3× 123 1.8× 12 469
Robert R. Henry 230 0.6× 143 1.2× 107 1.0× 209 2.6× 21 0.3× 8 543
Thalia Marie Blicher 376 0.9× 284 2.3× 86 0.8× 45 0.6× 15 0.2× 10 492
Y. G. Kim 431 1.1× 225 1.8× 146 1.4× 25 0.3× 74 1.1× 7 492
Natalie Houwing 129 0.3× 71 0.6× 130 1.2× 48 0.6× 55 0.8× 11 546
Moon Kwoun 254 0.6× 71 0.6× 58 0.5× 48 0.6× 37 0.5× 7 436
R. Qiu 460 1.1× 171 1.4× 230 2.1× 27 0.3× 23 0.3× 5 481
Laura Heenan 451 1.1× 163 1.3× 136 1.3× 90 1.1× 7 0.1× 7 517

All Works

Loading papers...

Rankless by CCL
2026